Albireo

Albireo appoints Cooper as CEO

Thursday, September 24, 2015

Ron Cooper has joined Albireo, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH and gastrointestinal disorders, as president and chief executive officer.

[Read More]